• Karine Levesque, Claire Coqueblin, Bernard Guillot, participants of round table n3 of Giens XXIX : Aubourg Lucie 4 Avouac Bernard , Lucie Aubourg, Bernard Avouac, Cédric Carbonneil, Michel Cucherat, Patricia Descamps-Mandine, Serge Hanoka, Marcel Goldberg, Anne Josseran, François Parquin, Séverine Pitel, Christelle Ratignier, Odile Sechoy, Karine Szwarcenstein, André Tanti, Emmanuel Teiger, and Nicolas Thevenet.
• Abbott Vascular, Rungis, France.
• Therapie. 2014 Jul 1; 69 (4): 303-21.

AbstractMedical devices are characterized notably by a wide heterogeneity (from tongue depressors to hip prostheses, and from non-implantable to invasive devices), a short life cycle with recurrent incremental innovations (from 18 months to 5 years), and an operator-dependent nature. The objective of the current round table was to develop proposals and recommendations concerning the prerequisites needed in order to meet the French health authorities expectations concerning requests for post-approval studies for medical devices, required in cases where short and long-term consequences are unknown. These studies, which are the responsibility of the manufacturer or the distributor of the medical device, are designed to confirm the role of the medical device in the therapeutic management strategy in a real-life setting. There are currently approximately 150 post-approval studies underway, mainly concerning class III devices, and the majority face difficulties implementing the study or meeting the study objectives. In light of this, the round table endeavored to clearly identify the conditions for implementation of post-approval studies specific to the characteristics of medical devices. Various areas of progress have been envisaged to improve the performance of these studies, and by consequence, the efficiency of reimbursement of medical devices by the national health insurance. These include providing manufacturers with the opportunity to better anticipate post-approval requirements, defining a study-specific primary objective, integrating a phase allowing dialogue between the manufacturer, the health authorities and the scientific committee, and increasing awareness and training of health professionals on the impact of post-approval clinical studies in terms of the reimbursement of medical devices by the national insurance.© 2014 Société Française de Pharmacologie et de Thérapeutique.

18 keywords...

hide…